Emcure Pharma to launch DCGI approved oral Covid-19 drug, molnupiravir in a week’s time in India

Emcure Pharmaceuticals Limited (EPL) has received an Emergency Use Authorisation (EUA) approval from the Drug Controller General of India for the launch of molnupiravir, an investigational oral anti-viral drug, for the treatment of mild Covid-19. EPL plans to launch molnupiravir under the brand name Lizuvira in the Indian market.

As the need for such a drug is imminent in the face of emerging challenges in covid-19 treatment, EPL will endeavour to deliver Lizuvira (molnupiravir) in a week's time. A toll-free helpline will be dedicated to help the doctors and patients access the product.

Leave a Reply